Immunotherapy has revolutionized the way we treat conditions such as cancer. Some of the most striking outcomes have been observed in adoptive cell transfer (ACT). At the forefront of this fast-moving field is CD19 targeted chimeric antigen receptor (CAR) T cell therapy, which has been approved by the Food and Drug Administration for the treatment of refractory pre-B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma among others.
- Are consistent for your cell therapy and immunology development needs
- Maintain a high standard for accuracy and sensitivity
- Can fit into your workflow
